During the past decade, Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 7 clinical trials were completed, i.e. on average, 87.5% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych" #1 collaborator was "Chugai Pharmaceutical" with 3 trials as a collaborator and "Baxalta Innovations GmbH, now part of Shire" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych" are "Hemophilia A" (7 trials), "B-cell Non-Hodgkin Lymphoma" (1 trials), "Lymphoma" (1 trials), "Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor" (1 trials) and "Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor" (1 trials). Many other conditions were trialed in "Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych" in a lesser frequency.

Most popular intervention types in "Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych" are "Drug" (9 trials). Other intervention types were less common.

The name of intervention was led by "Emicizumab" (5 trials), "Polatuzumab Vedotin" (2 trials), "Atezolizumab [TECENTRIQ]" (1 trials), "Bypassing Agents" (1 trials) and "Cyclophosphamide" (1 trials). Other intervention names were less common.

The vast majority of trials in "Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych" are 9 trials for "All" genders.

Currently, there are NaN active trials in "Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych, 2 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".